LinkMed: Interim report January - September, 2008

LinkMed: Interim report January - September, 2008

Group financial development July - September 
Following the acquisition of 100 percent of the shares of Olerup SSP AB, LinkMed
is now reported as a group.
• Net sales totaled SEK 16.8 million
• Results of investing activities were SEK 0 million
• Net income after tax was SEK 6.4 million
• Basic earnings per share was SEK 0.73 
• Equity per share was SEK 57.6 
• Equity/assets ratio was 69 percent

Parent company financial development January- September
• Results of investing activities were SEK 0 million (0)
• Other revenue totaled SEK 2.9 million (3.7)
• Net loss after tax was SEK 9.3 million (-5.9)

Key events in the third quarter
• LinkMed acquires 100 percent of Olerup SSP AB 
• AbSorber receives FDA clearance to sell XM-ONE® in the U.S.
• LinkMed participates in AnaMar Medical's new share issue with SEK 10 million

CEO Ingemar Lagerlöf's commentary on the third quarter 2008:
”Following the acquisition of the transplantation sector company Olerup SSP AB
in the third quarter, LinkMed is now a group, with Olerup SSP as a wholly owned
subsidiary. The acquisition gives us the opportunity to, in collaboration with
our transplantation sector company AbSorber, to build a unique and considerably
larger transplantation sector company with a strong future pipeline. The
acquisition strengthens LinkMed's financial position with a strong cash flow.
Through the acquisition of Olerup SSP, LinkMed reports profit in the third
quarter.” 

For additional information please contact:
Ingemar Lagerlöf, CEO LinkMed, cell +46 8 (0)70-873 2733 or e-mail
ingemar.lagerlof@linkmed.se 
Okee Williams, Portfolio Manager, cell +46 (0)70- 600 5364 or e-mail
okee.williams@linkmed.se


LinkMed develops life-science companies in collaboration with innovators and
other financiers. By contributing entrepreneurship and capital, LinkMed has
created a portfolio of one subsidiary and eleven associated companies, four in
drug development and biotechnology and seven in diagnostics and medical
technology. LinkMed's role changes as its portfolio companies develop. The
emphasis moves from operational to strategic and the entrepreneurship role
evolves into active Board work. The company's principal owners are FastPartner,
Koncentra Holding, and the founder Ingemar Lagerlöf. The LinkMed share is listed
on the OMX Nordic Exchange Stockholm in the small-cap sector (ticker:LMED).